Physician profile
Ghassan Abusaid
NPI 1487858072
$23,412.18
in general payments reported to CMS, 2019-2025
44 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,659 · 2020: $2,194 · 2021: $2,652 · 2022: $4,776 · 2023: $5,101 · 2024: $4,481 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,365 · Travel and Lodging: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,364.76 |
| Travel and Lodging | $1,765.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,800.95 | 2019-2024 | Optis, Diamondback Coronary, Amplatzer Amulet |
| Medtronic, INC. | $2,892.95 | 2021-2025 | Corevalve Evolut R, Harmony, Acist Rxi System |
| Penumbra, INC. | $1,726.32 | 2022-2025 | Indigo System |
| Edwards Lifesciences Corporation | $1,396.15 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Ekos Corporation | $1,327.61 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $1,132.53 | 2019-2025 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $1,108.94 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,022.24 | 2019-2025 | Eliquis, Camzyos |
| Abiomed | $949.63 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $873.65 | 2019-2025 | |
| Pfizer INC. | $704.48 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $489.58 | 2019-2025 | Lifevest |
| Cardiovascular Systems INC. | $464.16 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $395.42 | 2020-2025 | Onpattro |
| Inari Medical, INC. | $377.83 | 2019-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $322.74 | 2022-2023 | Auryon Laser System 100-120 Vac |
| Merck Sharp & Dohme LLC | $259.89 | 2021-2024 | Verquvo |
| Medtronic Vascular, INC. | $237.38 | 2019-2020 | |
| Atricure, INC. | $153.39 | 2024 | |
| Cvrx, INC. | $152.15 | 2023 | Barostim Neo System |
| Philips North America LLC | $147.78 | 2025 | IV Other |
| Amgen INC. | $142.75 | 2021-2025 | Repatha, Repatha |
| Livanova USA, INC. | $134.60 | 2020 | |
| Cardiva Medical, INC. | $124.99 | 2024 | Savvywire |
| Shockwave Medical, INC | $123.68 | 2020 | |
| Scpharmaceuticals INC. | $114.47 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $100.50 | 2020-2025 | Farxiga, Brilinta |
| Acist Medical Systems, INC. | $100.28 | 2022-2024 | |
| Novo Nordisk INC | $98.86 | 2025 | Wegovy |
| Boston Scientific Corporation | $88.38 | 2022-2024 | Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.02 | 2024-2025 | Jardiance |
| Esperion Therapeutics, INC. | $71.25 | 2022-2023 | Nexletol |
| United Therapeutics Corporation | $39.42 | 2020-2025 | Tyvaso |
| Surmodics, INC. | $38.13 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $37.17 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $29.28 | 2024 | Evkeeza, Praluent |
| Stryker Corporation | $26.53 | 2025 | Flowtriever |
| Kiniksa Pharmaceuticals, LTD. | $26.39 | 2021 | |
| Impulse Dynamics (USA) INC. | $23.97 | 2024 | Optimizer |
| Glaxosmithkline, LLC. | $20.80 | 2025 | Shingrix, Arexvy |
| Lantheus Medical Imaging, INC. | $18.73 | 2019 | |
| Chiesi USA, INC. | $17.75 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $13.71 | 2024 | Arcalyst |
| Convatec INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghassan Abusaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.